CKD Bio Corp.

KOSE:A063160 주식 보고서

시가총액: ₩135.8b

CKD Bio 과거 수익 실적

과거 기준 확인 0/6

CKD Bio's earnings have been declining at an average annual rate of -121.1%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 3.6% per year.

주요 정보

-121.1%

수익 성장률

-121.1%

EPS 성장률

Pharmaceuticals 산업 성장11.3%
매출 성장률3.6%
자기자본 수익률-17.6%
순이익-14.5%
최근 수익 업데이트30 Sep 2023

최근 과거 실적 업데이트

Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential

Nov 30
Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential

Recent updates

What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition

Feb 28
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition

Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?

Feb 01
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?

CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt

Jan 11
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt

What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us

Dec 21
What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us

Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential

Nov 30
Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential

수익 및 비용 분석

CKD Bio 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

KOSE:A063160 수익, 비용 및 수입 (KRW Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 23159,935-23,13015,05716,277
30 Jun 23155,183-20,23315,37715,272
31 Mar 23152,876-18,40315,25115,341
31 Dec 22156,042-16,70315,51315,432
30 Sep 22154,395-10,46213,97113,939
30 Jun 22154,759-11,22213,75012,777
31 Mar 22155,569-5,82113,24611,940
31 Dec 21142,238-6,57712,58511,516
30 Sep 21135,760-6,73012,10510,878
30 Jun 21130,483-1,11111,35510,667
31 Mar 21127,7411,77111,10910,114
31 Dec 20124,6006,20710,5389,118
30 Sep 20135,77310,6649,8739,900
30 Jun 20138,04212,6339,85210,455
31 Mar 20136,26512,4469,71810,584
31 Dec 19137,18412,26510,05710,704
30 Sep 19129,52910,5639,9139,919
30 Jun 19127,1349,6059,3479,074
31 Dec 18124,5107,9568,5307,881

양질의 수익: A063160 is currently unprofitable.

이익 마진 증가: A063160 is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: Insufficient data to determine if A063160's year-on-year earnings growth rate was positive over the past 5 years.

성장 가속화: Unable to compare A063160's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: A063160 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).


자기자본 수익률

높은 ROE: A063160 has a negative Return on Equity (-17.58%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기